Skip to main content

Table 4 Multivariate Cox proportional hazard model analysis of PFS and OS

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Variable

Progression-free survival

Overall survival

Hazard ratio

95% CI

P value

Hazard ratio

95% CI

P value

Histology

      

ADC vs non-ADC

1.154

0.637-2.622

0.255

1.118

0.563-2.527

0.248

Performance status

      

0-1 vs 2-3

1.845

1.052-2.995

0.114

2.532

1.219-4.325

0.013

Disease stage

      

IIIB vs IV

0.875

0.317-2.152

0.416

1.272

0.428-2.257

0.167

EGFR status

      

Wild-type vs mutation

2.726

1.415-4.655

0.011

2.615

1.338-4.524

0.014

MUC1 mRNA at B0

      

Positivity vs negativity

2.359

1.155-4.326

0.018

2.494

1.536-4.721

0.015

MUC1 mRNA at B4w

      

Positivity vs negativity

2.855

1.512-4.779

0.007

2.842

1.975-5.013

0.009

VEGF mRNA at B0

      

Positivity vs negativity

2.453

1.415-4.592

0.013

2.577

1.482-4.683

0.011

VEGF mRNA at B4w

      

Positivity vs negativity

3.012

2.103-5.148

0.004

2.910

1.971-5.106

0.006

  1. ADC, adenocarcinoma.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us